MG53 as a Novel Therapeutic Protein to Treat Acute Lung Injury
Abstract
Lung injury has several inciting etiologies ranging from trauma (contusion and hemorrhage) to ischemia reperfusion injury. Reflective of the injury, tissue and cellular injury increases proportionally with the injury stress and is an area of potential intervention to mitigate the injury. This study aims to evaluate the therapeutic benefits of recombinant human MG53 (rhMG53) protein in porcine models of acute lung injury (ALI).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2021
- Source ID
- 10.1093/milmed/usaa313
Entities
People
- Bryan A. Whitson
- Chuanxi Cai
- Greg J. Beilman
- Haichang Li
- Jianjie Ma
- Kristine Mulier
- Sylvester M Black
- Tao Tan
- Xinyu Zhou
Organizations
- National Institutes of Health
- Ohio State University
- United States Department of Defense
- University of Minnesota